Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 8731 https://www.adaptimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics PLC -

What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? - Aug 16th, 2019 9:23 am
Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT - Aug 4th, 2019 12:46 pm
Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript - Aug 1st, 2019 8:24 pm
New Executive Team Announced at Adaptimmune - Aug 1st, 2019 5:15 am
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update - Aug 1st, 2019 5:15 am
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019 - Jul 29th, 2019 2:05 pm
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS - Jul 25th, 2019 6:00 am
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center - Jul 22nd, 2019 6:00 am
How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay? - Jul 18th, 2019 9:00 am
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses - Jul 18th, 2019 6:00 am
Athenex (ATNX) in Focus: Stock Moves 6.5% Higher - Jul 9th, 2019 9:23 am
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why - Jul 9th, 2019 7:00 am
Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds? - Jun 29th, 2019 3:37 pm
Hedge Funds Piled Into This Stock Right Before Its 40% Ascend - Jun 27th, 2019 12:54 pm
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer - Jun 27th, 2019 6:00 am
Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It - May 28th, 2019 8:14 am
AdaptImmune partners to advance promising cancer immunotherapies - May 15th, 2019 10:28 am
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products - May 15th, 2019 6:00 am
Adaptimmune Reports First Quarter 2019 Financial Results - May 6th, 2019 5:30 am
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors - May 6th, 2019 5:00 am